OCM
IBRX icon

One Capital Management’s ImmunityBio IBRX Stock Holding History

One Capital Management’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$298K Hold
38,910
– – 0.01% 461
2026
Q1 		$298K Hold
38,910
– – 0.01% 460
2025
Q4 		$77K Hold
38,910
– – ﹤0.01% 512
2025
Q3 		$95.7K Hold
38,910
– – ﹤0.01% 475
2025
Q2 		$103K Buy
+38,910
New +$105K ﹤0.01% 458

Other funds holding IBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

One Capital Management's IBRX Position: Q2 2026 in Review

One Capital Management held its ImmunityBio (IBRX) position steady in Q2 2026 at 38,910 shares worth $298K. The position accounts for 0.01% of the portfolio, ranked #461.

One Capital Management first reported a position in IBRX in Q2 2025 and has held it in 5 quarters since. 405 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

  • One Capital Management held 38,910 shares of ImmunityBio worth $298K as of Q2 2026.
  • One Capital Management left its ImmunityBio share count unchanged in Q2 2026.
  • ImmunityBio made up 0.01% of One Capital Management's portfolio in Q2 2026, its #461 holding.
  • One Capital Management first reported a position in ImmunityBio in Q2 2025 and has held it in 5 quarters since.
  • 405 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on One Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.